Cardiovascular Drugs Market Approximately US$ 80.0 Bn in 2016 and is anticipated to register CAGR of over 1.0% from 2017 to 2030

Cardiovascular diseases (CVDs) comprise disorders and conditions related to circulatory system which include heart and vascular system. The global cardiovascular drugs market was valued approximately US$ 80.0 Bn in 2016 and is anticipated to register CAGR of over 1.0% from 2017 to 2025 to reach value of approximately US$ 91.0 Bn by 2025. Drug classes used to treat cardiovascular indications such as hyperlipidemia, hypertension are likely to fuel expansion of the global cardiovascular drugs market from 2017 to 2025.

Get the sample copy of report@ https://qyresearchmedical.com/sample/112022

Cardiovascular diseases are one of the leading causes of death worldwide. According to American Heart Association, in 2015, approximately 41.5% of the U.S. population was suffering from some form of cardiovascular disease, it is further estimated that this prevalence is likely to increase to 45% by 2035. Sedentary lifestyle, changing dietary habits and surge in associated risk factors are likely to increase the number of patients with cardiovascular diseases. According to the Centers for Disease Control and Prevention (CDC) of the U.S., high blood pressure, high cholesterol, and smoking are key risk factors for heart disease. About half of the population of the U.S. (47%) have at least one of these three risk factors. To treat the diseases, key players are investing in to develop new drugs with better efficacy and less side effects. Launch of PCSK9 inhibitors (Praluent) for treating hyperlipidemia in 2016 is likely to fuel expansion of anti-hyperlipidemia drugs market segment by 2025 augmenting global cardiovascular drugs market. However, recent expiry of patent exclusivity of blockbuster cardiovascular drugs has led to plethora of generic drugs which is likely to hamper global cardiovascular drugs market.

There are many unmet needs in global cardiovascular drugs market which create huge opportunities for existing players and new entrants in global market. Biologics provide ample opportunities for players operating in the global cardiovascular drugs market. Recent developments in biologic cardiovascular drugs such as Pfizer’s PCSK9 inhibitor, Esperion Therapeutics’ novel LDL-lowering drug ETC-1002 and Merck’s CETP inhibitor anacetrapib, uncovers the potential of these drugs. Blockbuster drugs are losing their patent exclusivity which has set a trend to introduce generics in market by local as well as international players. For instance, Crestor launched by Astrazeneca and indicated for the treatment of hyperlipidemia, lost patent in early 2016 and in April 2016, the U.S. FDA approved first generic to this drug to Watson Pharmaceuticals Inc.

View full report@ https://qyresearchmedical.com/report/cardiovascular-drugs-market-drug-class-anti-hyperlipidemics-anti-hypertensives-anti-coagulants-anti-fibrinolytics-anti-arrhythmic-distribution-channels-hospital-pharmacies-online-pharmacies-retail-pharma-017-2030/112022

The global cardiovascular drugs market has been segmented on the basis of drug class, indication, distribution channel and geography. Among drug class, anti-clotting agents segment is projected to lead the market and is expected to continue its dominance during the forecast period followed by anti-hyperlipidemia segment. Introduction of new anti-hyperlipidemia drug such as PCSK9 Inhibitor (Praluent) and increasing incidences of hyperlipidemia is likely to propel expansion of the segment. Among indications, hypertension was the leading revenue generating segment in 2016 and it is likely to continue its dominance during the forecast period. Arrhythmia segment of indication is likely to lose its market share during the forecast period owing to shift of preference from anti-arrhythmia drugs to advanced implantable cardiovascular devices such as pacemakers. Among various distribution channels, retail pharmacies was the leading distribution channel in 2016 and is likely to account for leading share during the forecast period.

Geographically, North America captured lion’s share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives  for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East & Africa.

Key companies operating in the global cardiovascular drugs market and profiled in the report include AstraZeneca plc., Bayer AG, Merck & Co., Inc., Sanofi, Pfizer, Inc., Eli Lilly & Company among others. These players are adopting organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base and garner market share. For instance, in December 2015, AstraZeneca acquired ZS pharma which added pipeline biological drug for chronic heart failure to AstraZeneca’s existing cardiovascular drugs pipeline. In another instance, in 2016, Sanofi launched new cardiovascular drug Praluent for treatment of hyperlipidemia.

Alarming Rise in the Cases of Cardiovascular Diseases and Disorders to Propel the Growth Opportunities across the Cardiovascular Drugs Market

Cases related to cardiovascular disorders and diseases have increase manifold over the years. The growing prevalence of cardiovascular diseases has resulted in the formation of novel drugs and formulations for rapid treatment. The growing demand for such products will bring immense growth opportunities for the cardiovascular drugs market during the assessment period of 2017-2025.

Cardiovascular diseases include coronary heart disease, hyperlipidemia, myocardial infarction, disorders of the blood vessels, and others. The drugs used to treat all these diseases and disorders are known as cardiovascular drugs. The heightening popularity of these drugs for quick relief from a number of diseases will bring immense growth prospects across the forecast period.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112022/2900

Heart disease is the leading cause of death in the United States as per the study by the Centers for Disease Health and Prevention (CDC),. The CDC also estimates that one individual in the United States dies every second from cardiovascular disease. These alarming statistics raise concerns about the need for controlling the menace. Thus, all these aspects are laying a red carpet of growth for the cardiovascular drugs market.

The players in the cardiovascular drugs market are always involved in research and development activities. They invest heavily in these activities for exploring novel insights and discovering new formulations, ultimately leading to a boost in revenues.

The players also indulge in strategic collaborations. The collaborations assist in propelling the influence of the players in the cardiovascular drugs market. Mergers, acquisitions, collaborations, and joint ventures form the foundation of growth. Thus, all these factors help in increasing the growth rate of the cardiovascular drugs market.

The COVID-19 pandemic has a little negative impact on the cardiovascular drugs market. The healthcare and pharmaceuticals sector was exempted from the strict lockdown restrictions and hence, the cardiovascular drugs market was protected from disruptions.

The global cardiovascular drugs market has been segmented as follows:

Drug Class

  • Renin-Angiotensin System Blockers
  • ACE Inhibitors
  • Angiotensin Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Anti-Clotting Agents
  • Anti-Coagulants
  • Platelet Aggregation Inhibitors
  • Antihyperlipidemics
  • Other Antihypertensive
  • Calcium Channel Blockers
  • Others

Indication

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Peripheral Artery Disease
  • Arrhythmia
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • South Africa
  • GCC Region
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global CVD Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Developments
4.2. Overview
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.5. Global CVD Market Analysis and Forecasts, 2015–2025
4.5.3. Market Revenue Projections (US$ Mn)
4.6. CVD Market – Global Supply Demand Scenario
4.7. Porter’s Five Force Analysis
4.9. Market Outlook

5. Global CVD Market Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings
5.4. Market Value Forecast By Drug Class , 2015–2025
5.4.1. Renin-Angiotensin System Blockers
5.4.1.1. ACE Inhibitors
5.4.1.2. Angiotensin Receptor Blockers
5.4.2. Beta Blockers
5.4.3. Diuretics
5.4.4. Anti-Clotting Agents
5.4.4.1. Anti-Coagulants
5.4.4.2. Platelet Aggregation Inhibitors
5.4.5. Antihyperlipidemics
5.4.6. Other Antihypertensives
5.4.7. Calcium Channel Blockers
5.4.8. Others
5.5. Market Attractiveness By Drug Class

6. Global CVD Market Analysis and Forecasts, By Indications
6.1. Introduction & Definition
6.2. Key Findings
6.4. Market Value Forecast By Indications , 2015–2025
6.4.1. Hypertension
6.4.2. Hyperlipidemia
6.4.3. Coronary Artery Disease
6.4.4. Peripheral Artery Disease
6.4.5. Arrhythmia
6.4.6. Others
6.5. Market Attractiveness By Indications

7. Global CVD Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings
7.4. Market Value Forecast By Distribution Channel , 2015–2025
7.4.1. Hospital Pharmacy
7.4.2. Retail Pharmacy
7.4.3. Online Pharmacy
7.5. Market Attractiveness By Distribution Channel

8. Global CVD Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Country/Region

9. North America CVD Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Drug Class , 2015–2025
9.2.1. Renin-Angiotensin System Blockers
9.2.1.1. ACE Inhibitors
9.2.1.2. Angiotensin Receptor Blockers
9.2.2. Beta Blockers
9.2.3. Diuretics
9.2.4. Anti-Clotting Agents
9.2.4.1. Anti-Coagulants
9.2.4.2. Platelet Aggregation Inhibitors
9.2.5. Antihyperlipidemics
9.2.6. Other Antihypertensives
9.2.7. Calcium Channel Blockers
9.2.8. Others
9.3. Market Value Forecast By Indications , 2015–2025
9.3.1. Hypertension
9.3.2. Hyperlipidemia
9.3.3. Coronary Artery Disease
9.3.4. Peripheral Artery Disease
9.3.5. Arrhythmia
9.3.6. Others
9.4. Market Value Forecast By Distribution Channel , 2015–2025
9.4.1. Hospital Pharmacy
9.4.2. Retail Pharmacy
9.4.3. Online Pharmacy
9.5. Market Value Forecast By Country , 2015–2025
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By Indications
9.6.3. By Distribution Channel
9.6.4. By Country

10. Europe CVD Market Analysis and Forecast

…….

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112022/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi